AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6338990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and ampicillin
Number of subjects: 283
Study 6338990 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 283
Study 31131501 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (Exparel) administered via transversus abdominis plane (TAP) block
Number of subjects: 46
Study 30518055 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week nutrition education
Number of subjects: 71
Study 30518055 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials
Number of subjects: 71
Study 26238968 — intervention group
Group type: EXPERIMENTAL
Intervention: l-DOPA
Number of subjects: 40
Study 26238968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23850615 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Number of subjects: 37
Study 21697609 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPC group II (3 × 5‐min cycles of right upper arm ischemia and 5‐min reperfusion combined with 2 × 10‐min cycles of right upper leg ischemia and 10‐min reperfusion)
Number of subjects: 75
Study 21697609 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPC group II
Number of subjects: 75
Study 21697609 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 19549060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 0
Study 19549060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 0
Study 19549060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 0
Study 19549060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16352669 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyline (GnRH antagonist) for medical castration
Number of subjects: 12
Study 16352669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16352669 — intervention group
Group type: COMPARATOR
Intervention: Acyline plus daily testosterone gel
Number of subjects: 12
Study 15303634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 7 days
Number of subjects: 324
Study 15303634 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 1 g/125 mg three times daily for 10 days
Number of subjects: 324
Study 11295696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m-MIBI gated SPECT
Number of subjects: 56
Study 11295696 — intervention group
Group type: COMPARATOR
Intervention: Tl-201 gated SPECT
Number of subjects: 56
Study 8818261 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut sutures
Number of subjects: 55
Study 8818261 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid sutures
Number of subjects: 55
Study 8818261 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910 sutures
Number of subjects: 55
Study 1441674 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotalcite 1000 mg q.i.d.
Number of subjects: 159
Study 1441674 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg at night
Number of subjects: 159
Study 6737208 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise treatment
Number of subjects: 43
Study 6737208 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (relaxation exercises)
Number of subjects: 43
Study 6737208 — intervention group
Group type: COMPARATOR
Intervention: No-treatment condition
Number of subjects: 43
Study 31756444 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted levels of follicle stimulating hormones
Number of subjects: 2488
Study 31756444 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher predicted levels of luteinizing hormone
Number of subjects: 2488
Study 29845672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pentosan polysulfate (Na‐PPS) 50 mg subcutaneously twice daily
Number of subjects: 109
Study 29845672 — intervention group
Group type: COMPARATOR
Intervention: Standard thromboprophylaxis (enoxaparin 40 mg subcutaneously once daily or fondaparinux 2.5 mg once daily for Muslim women)
Number of subjects: 109
Study 27328952 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (80 mg)
Number of subjects: 1171
Study 27328952 — intervention group
Group type: COMPARATOR
Intervention: Low dose atorvastatin (10 mg)
Number of subjects: 1171
Study 27328952 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1171
Study 23436336 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide MMX 9 mg
Number of subjects: 410
Study 23436336 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide MMX 6 mg
Number of subjects: 410
Study 23436336 — intervention group
Group type: EXPERIMENTAL
Intervention: Entocort EC 9 mg
Number of subjects: 410
Study 23436336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 22835510 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d lutein
Number of subjects: 108
Study 22835510 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d lutein
Number of subjects: 108
Study 22835510 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d lutein plus 10 mg/d zeaxanthin
Number of subjects: 108
Study 22835510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 20020090 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of non-university surgical departments into multicenter trials; no specific intervention details available.
Number of subjects: 0
Study 17698432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure CO2 insufflation (LPLC)
Number of subjects: 80
Study 17698432 — intervention group
Group type: COMPARATOR
Intervention: Abdominal wall lifting (GLC)
Number of subjects: 80
Study 15289993 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 32.5 g/200 ml (G32.5)
Number of subjects: 12
Study 15289993 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 75 g/200 ml (G75)
Number of subjects: 12
Study 15289993 — intervention group
Group type: COMPARATOR
Intervention: Aspartame 0.6 g/200 ml (A, placebo)
Number of subjects: 12
Study 12170197 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EBT) after PTA (192-Iridium)
Number of subjects: 24
Study 12170197 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy after PTA
Number of subjects: 24
Study 10443598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 1 MAC Xe
Number of subjects: 43
Study 10443598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 0.7 MAC Xe
Number of subjects: 43
Study 10443598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with 0.7 MAC N2O
Number of subjects: 43
Study 7665880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative contamination by Haemophilus species
Number of subjects: 193
Study 7665880 — intervention group
Group type: COMPARATOR
Intervention: Negative cultures for Haemophilus species
Number of subjects: 193
Study 2132289 — intervention group
Group type: EXPERIMENTAL
Intervention: Morniflumate (700 mg bid)
Number of subjects: 60
Study 2132289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (300 mg bid)
Number of subjects: 60
Study 2132289 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (10 ml syrup equivalent to 500 mg tid)
Number of subjects: 60
Study 582394 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tinofedrine i.v.
Number of subjects: 10
Study 582394 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 31358022 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulated Lactobacillus rhamnosus HN001 (6 × 10^9 colony-forming units/day)
Number of subjects: 152
Study 31358022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal containing 4 g β-glucan
Number of subjects: 152
Study 31358022 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 152
Study 31358022 — intervention group
Group type: COMPARATOR
Intervention: Calorie-matched control cereal
Number of subjects: 152
Study 31358022 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulated Lactobacillus rhamnosus HN001 and cereal containing 4 g β-glucan
Number of subjects: 152
Study 28767288 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) consolidation with reduced doses of anthracyclines
Number of subjects: 101
Study 28767288 — intervention group
Group type: COMPARATOR
Intervention: Historical control (AIDA 0493) with higher anthracycline doses and no ATO consolidation
Number of subjects: 101
Study 25030327 — intervention group
Group type: EXPERIMENTAL
Intervention: Contasure-Needleless (C-NDL®)
Number of subjects: 257
Study 25030327 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tension-free vaginal tape (TVT-O®)
Number of subjects: 257
Study 23642147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water injections (0.1 to 0.3 millilitres)
Number of subjects: 1866
Study 23642147 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 1866
Study 21859657 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.10 g/kg·d
Number of subjects: 20
Study 21859657 — intervention group
Group type: COMPARATOR
Intervention: 1.02 g/kg·d
Number of subjects: 20
Study 19922897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 50 mg
Number of subjects: 16
Study 19922897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 100 mg
Number of subjects: 16
Study 19922897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 200 mg
Number of subjects: 16
Study 19922897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17084844 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E2/NETA 1 mg/0.5 mg
Number of subjects: 90
Study 17084844 — intervention group
Group type: COMPARATOR
Intervention: Intranasal E2/NET 175 microg/275 microg
Number of subjects: 90
Study 17084844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 90
Study 14700647 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes (eyes that experienced optic neuritis)
Number of subjects: 319
Study 14700647 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with multiple sclerosis (MS)
Number of subjects: 319
Study 14700647 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent optic neuritis
Number of subjects: 319
Study 14700647 — intervention group
Group type: EXPERIMENTAL
Intervention: National Eye Institute Visual Function Questionnaire
Number of subjects: 319
Study 12575586 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with Antike capsule (AC)
Number of subjects: 89
Study 12575586 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 89
Study 9491025 — intervention group
Group type: EXPERIMENTAL
Intervention: Green prescription (written exercise advice)
Number of subjects: 456
Study 9491025 — intervention group
Group type: COMPARATOR
Intervention: Verbal advice
Number of subjects: 456
Study 7513171 — intervention group
Group type: COMPARATOR
Intervention: Biopsy prior to transplantation, shortly after opening of reanastomosis, at least once postoperatively (days 7‐10)
Number of subjects: 41
Study 7513171 — intervention group
Group type: COMPARATOR
Intervention: Follow-up biopsies from non-rejecting and rejecting patients
Number of subjects: 41
Study 7513171 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased infiltration of T cells and macrophages
Number of subjects: 41
Study 7513171 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tubular and endothelial staining for MHC class II, ICAM‐1, and VCAM‐1
Number of subjects: 41
Study 7513171 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong leukocytic expression of VLA‐4 and LFA‐1 alpha/beta
Number of subjects: 41
Study 3369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol, 200 micrograms via Aerochamber
Number of subjects: 30
Study 3369751 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 30
Study 30012812 — intervention group
Group type: EXPERIMENTAL
Intervention: D6 intervention (12 sessions over 12 months)
Number of subjects: 334
Study 30012812 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 334
Study 27448179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 24
Study 26122678 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability balls as chairs
Number of subjects: 0
Study 26122678 — intervention group
Group type: COMPARATOR
Intervention: Chairs as usual (control)
Number of subjects: 0
Study 23443608 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of 0.5 Gy
Number of subjects: 457
Study 23443608 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of 1.0 Gy
Number of subjects: 457
Study 23443608 — intervention group
Group type: COMPARATOR
Intervention: Both 0.5 Gy and 1.0 Gy groups
Number of subjects: 457
Study 20719808 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-administered version of the Word Memory Test (WMT)
Number of subjects: 125
Study 20719808 — intervention group
Group type: COMPARATOR
Intervention: Orally administered version of the Word Memory Test (WMT)
Number of subjects: 125
Study 18766404 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (5 x 5 Gy) with immediate total mesorectal excision (TME)
Number of subjects: 312
Study 18766404 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy, bolus 5-fluorouracil and leucovorin) with delayed TME
Number of subjects: 312
Study 15671107 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg 17beta‐estradiol (ET)
Number of subjects: 25
Study 15671107 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg 17beta‐estradiol combined with 10 mg dydrogesterone (EPT)
Number of subjects: 25
Study 15671107 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 12906976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg for 6 weeks
Number of subjects: 150
Study 10496712 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐ProUK 2 mg/hr
Number of subjects: 241
Study 10496712 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐ProUK 4 mg/hr
Number of subjects: 241
Study 10496712 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐ProUK 8 mg/hr
Number of subjects: 241
Study 10496712 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (4,000 IU/min for 4 hrs, then 2,000 IU/min)
Number of subjects: 241
Study 8604260 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (25 to 50 microg/kg/min over 24 hours)
Number of subjects: 18
Study 8604260 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion of normal saline
Number of subjects: 18
Study 1682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Reticulin antibodies
Number of subjects: 122
Study 1682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliadin antibodies
Number of subjects: 122
Study 1682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of reticulin-antibody-positive relatives
Number of subjects: 122
Study 1682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic comparison of reticulin-antibody-positive relatives
Number of subjects: 122
Study 1682735 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic comparison of gliadin-antibody-positive relatives
Number of subjects: 122
Study 7438470 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide
Number of subjects: 27
Study 7438470 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine
Number of subjects: 27
Study 7438470 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 30918101 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 100 U
Number of subjects: 184
Study 30918101 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 75 U
Number of subjects: 184
Study 30918101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 28646140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AGE diet
Number of subjects: 20
Study 25433040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (1-5 mg/kg/day) plus steroids
Number of subjects: 58
Study 25433040 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX (15-25 mg weekly) plus steroids
Number of subjects: 58
Study 25433040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin/MTX combination therapy plus steroids
Number of subjects: 58
Study 25433040 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone (placebo control)
Number of subjects: 58
Study 23833855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve block with bupivacaine 0.5% with epinephrine
Number of subjects: 27
Study 23833855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21640931 — intervention group
Group type: EXPERIMENTAL
Intervention: MGuard-based PCI
Number of subjects: 41
Study 19713649 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise group
Number of subjects: 0
Study 19713649 — intervention group
Group type: COMPARATOR
Intervention: Land exercise group
Number of subjects: 0
Study 16686567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group without expectancy instructions
Number of subjects: 48
Study 16686567 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with expectancy instructions
Number of subjects: 48
Study 16686567 — intervention group
Group type: COMPARATOR
Intervention: Placebo group without expectancy instructions
Number of subjects: 48
Study 16686567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group with expectancy instructions
Number of subjects: 48
Study 15457380 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic procedure
Number of subjects: 171
Study 15457380 — intervention group
Group type: COMPARATOR
Intervention: Open technique
Number of subjects: 171
Study 11253738 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nicorandil
Number of subjects: 11
Study 11253738 — intervention group
Group type: COMPARATOR
Intervention: No premedication (control)
Number of subjects: 11
Study 9280552 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol gel TX 11323 (A)
Number of subjects: 80
Study 9280552 — intervention group
Group type: COMPARATOR
Intervention: Transdermal matrix system delivering 50 micrograms/24 h of estradiol
Number of subjects: 80
Study 7687978 — intervention group
Group type: COMPARATOR
Intervention: 10 MU/m2 interferon‐alpha‐2a, three times a week for 6 months (group 1, n = 20)
Number of subjects: 38
Study 7687978 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/m2 of levamisole for 45 days, together with 10 MU/m2 of interferon‐alpha‐2a, three times a week for 6 months (group 2, n = 18)
Number of subjects: 38
Study 3737692 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (manipulation of the sacroiliac joint + moist heat + passive stretching)
Number of subjects: 20
Study 3737692 — intervention group
Group type: COMPARATOR
Intervention: Control Group (moist heat + passive stretching)
Number of subjects: 20
Study 30138355 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 138
Study 30138355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 26585044 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-session telephone brief motivational intervention on alcohol, delivered by a counselor trained in motivational interviewing during 6 weeks
Number of subjects: 730
Study 26585044 — intervention group
Group type: COMPARATOR
Intervention: Control intervention of a scripted home fire and burn safety education delivered in 3 calls
Number of subjects: 730
Study 24885915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain self-management course plus standard care
Number of subjects: 88
Study 24885915 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 88
Study 22260338 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion (PLF) with posterior instrumentation (group I)
Number of subjects: 80
Study 22260338 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF) with posterior instrumentation (group II)
Number of subjects: 80
Study 20630640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of Twinrix (720 ELISA units of inactivated hepatitis A virus and 20 μg of purified hepatitis B virus surface antigen) and Engerix-B (20 μg) at 0, 1, and 6 months plus Engerix-B, 40 μg, at month 2
Number of subjects: 96
Study 20630640 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B, 40 μg, at 0, 1, 2, and 6 months (control arm)
Number of subjects: 96
Study 17118102 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 33
Study 17118102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15574076 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture (1 g per 10 kg of body weight) for a period of 1 month
Number of subjects: 60
Study 15574076 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the same duration (control group)
Number of subjects: 60
Study 15574076 — intervention group
Group type: COMPARATOR
Intervention: Additional control group (20 subjects not engaged in physical training)
Number of subjects: 60
Study 11354523 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training A (90-80% vVO2 max)
Number of subjects: 0
Study 11354523 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training B (100-70% vVO2 max)
Number of subjects: 0
Study 11354523 — intervention group
Group type: COMPARATOR
Intervention: Interval training C (60 x 110% vVO2 max)
Number of subjects: 0
Study 9143733 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI)
Number of subjects: 21
Study 9143733 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity (LOH)
Number of subjects: 21
Study 7907348 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of ranitidine (6.25 mg/hr)
Number of subjects: 18
Study 7907348 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intravenous infusions of famotidine (20 mg every 12 hours)
Number of subjects: 18
Study 3316059 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY o 1248 (20 mg with breakfast)
Number of subjects: 7